Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells.
Tumor invasion and metastasis development is a multistep process involving adhesion molecules as well as tumor proteases. It has been reported that tumor cells lacking fibronectin (FN) expression and engineered to re-express FN showed a marked reduction in metastatic ability. Besides its effects on cell adhesion and migration, FN could be modulating other cellular events associated with the metastatic cascade. To test this hypothesis, we analyzed the production of urokinase-type plasminogen activator (uPA), and its receptor (uPAR), 2 molecules involved in the invasive phenotype, in cells over-expressing RGD wild-type FN (FNwt clones) or RGD-mutated FN (FN RGD-minus clones). Secreted uPA activity and antigen were significantly up-regulated in FN-expressing clones, although RGD-minus cells secreted approximately 50% less uPA than the FNwt ones. Interestingly, while control and FN RGD-minus clones were able to readily bind uPA to their surface, FNwt clones exhibited impaired uPA binding. Furthermore, treatment of the parental cell line as well as the control and FN-expressing clones with exogenous purified FN or RGD peptides induced up-regulation of uPA production and the reduction of uPA membrane binding, which was associated with lower expression of uPAR. This modulation by FN was found to be dependent on RGD sequence and beta1 integrin. These results strongly suggest a novel activity for the multifunctional glycoprotein FN regarding the regulation of uPA production as well as the capacity of tumor cells to bind uPA.
Urtreger
A J
AJ
Research Area, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina. aju@invrof.fmed.uba.ar
Aguirre Ghiso
J A
JA
Werbajh
S E
SE
Puricelli
L I
LI
Muro
A F
AF
Bal de Kier Joff
E
E
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D002465:Cell Movement; D004790:Enzyme Induction; D005353:Fibronectins / Q000235:genetics / Q000378:metabolism*; D019012:Integrin beta1 / Q000502:physiology; D015674:Mammary Neoplasms, Animal / Q000201:enzymology* / Q000473:pathology; D051379:Mice; D009842:Oligopeptides / Q000502:physiology; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000096:biosynthesis / Q000502:physiology; D055293:Receptors, Urokinase Plasminogen Activator; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis* / Q000378:metabolism
D000970:Antineoplastic Agents; D005353:Fibronectins; D019012:Integrin beta1; D009842:Oligopeptides; C524899:Plaur protein, mouse; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; C047981:arginyl-glycyl-aspartic acid; D014568:Urokinase-Type Plasminogen Activator